Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

Start doses of 5 mg and 10 mg with end dose of 20 mg. For oral administration.

Start doses of 5 mg and 10 mg with end doses of either 20 mg or 40 mg. For oral administration.

Start doses of 5 mg and 10 mg with end doses of either 20 mg, 40 mg or 60 mg. For oral administration.

Placebo semaglutide. For oral administration.

Placebo semaglutide with carrier. For oral administration.